Humoral Immune Response to CoronaVac in Turkish Adults

Humoral Immune Response to CoronaVac in Turkish Adults

While most approved vaccines are based on the viral spike protein or its immunogenic regions, inactivated whole-virion vaccines (e.g., CoronaVac) contain additional antigens that may enhance protection. This study analyzes short-term humoral responses against the SARS-CoV-2 spike (S1) and nucleocaps...

Full description

Bibliographic Details
Main Authors:	Yasemin Cosgun, Nergis Emanet, Ayten Öz Kamiloglu, Evelin Grage-Griebenow, Susann Hohensee, Sandra Saschenbrecker, Katja Steinhagen, Gulay Korukluoglu
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	Vaccines
Subjects:	CoronaVac COVID-19 nucleocapsid protein SARS-CoV-2 spike protein
Online Access:	https://www.mdpi.com/2076-393X/11/2/216

Similar Items

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
by: Samar Samoud, et al.
Published: (2023-08-01)

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
by: Thiago Cerqueira-Silva, et al.
Published: (2022-02-01)

Sobre a eficácia da CoronaVac no Twitter: conversações e aspectos políticos
by: Carina Luisa Ochi Flexor, et al.
Published: (2022-12-01)

Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
by: Bothamai Dechates, et al.
Published: (2023-03-01)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
by: Yun Shan Goh, et al.
Published: (2022-01-01)

Humoral and cellular immune responses to CoronaVac up to one year after vaccination
by: Priscilla Ramos Costa, et al.
Published: (2022-10-01)

Safety and immunogenicity of CoronaVac in healthy adults: A prospective observational multicenter real-world study in Henan Province, China
by: Benchen Rao, et al.
Published: (2024-12-01)

Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine
by: Cheng Cao, et al.
Published: (2023-10-01)

The Predictive Value of Gut Microbiota Composition for Sustained Immunogenicity following Two Doses of CoronaVac
by: Ho-Yu Ng, et al.
Published: (2024-02-01)

Risk of adverse events following CoronaVac's COVID-19 vaccination in women with and without autoimmunity
by: Stevent Sumantri, et al.
Published: (2023-03-01)

Metabolomics acts as a powerful tool for comprehensively evaluating vaccines approved under emergency: a CoronaVac retrospective study
by: Xinyu Liu, et al.
Published: (2023-07-01)

Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19
by: Wei Zhao, et al.
Published: (2022-06-01)

Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series
by: Nijasri C. Suwanwela, et al.
Published: (2022-01-01)

Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
by: Mine Durusu Tanriover, et al.
Published: (2022-11-01)

Humoral responses to the CoronoVac vaccine in healthcare workers
by: Gokhan Eyupoglu, et al.
Published: (2023-02-01)

How has research on the effectiveness and safety of COVID-19 vaccination been evaluated: a scope review with emphasis on CoronaVac
by: Juan C. Alzate-Ángel, et al.
Published: (2024-04-01)

Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination
by: Jianhua Li, et al.
Published: (2022-12-01)

Placental Transfer Immunity to the Newborns in a Twin Pregnant Women Vaccinated with Heterologous CoronaVac-ChAdOx1
by: Saipin Pongsatha, et al.
Published: (2023-01-01)

Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study
by: Ayakarn Ruenkham, et al.
Published: (2023-09-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report
by: Wanakorn Rattanawong, et al.
Published: (2021-08-01)

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
by: Daniel Leung, et al.
Published: (2022-09-01)

An Integrative Analysis of the Immune Features of Inactivated SARS-CoV-2 Vaccine (CoronaVac)
by: Zhujun Jiang, et al.
Published: (2022-05-01)

Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report
by: Ekachai Singhatiraj, et al.
Published: (2021-09-01)

Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
by: Alejandro Escobar, et al.
Published: (2022-01-01)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
by: Ruiqi Zhang, et al.
Published: (2022-04-01)

Hybrid Immunity Results in Enhanced and More Sustained Antibody Responses after the Second Sinovac-CoronaVac Dose in a Brazilian Cohort: DETECTCoV-19 Cohort
by: Bárbara Batista Salgado, et al.
Published: (2023-09-01)

Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration
by: Camille F. de Oliveira, et al.
Published: (2022-04-01)

Waning anti-SARS-CoV-2 receptor-binding domain total antibody in CoronaVac-vaccinated individuals in Indonesia [version 2; peer review: 2 approved]
by: Samsul Anwar, et al.
Published: (2023-04-01)

RESPOSTA CELULAR DE RESPONDEDORES E NÃO RESPONDEDORES ANTICÓRPICOS: ESTUDO EM PROFISSIONAIS DA SAÚDE VACINADOS COM CORONAVAC
by: Lais Teodoro da Silva, et al.
Published: (2023-10-01)

SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients
by: Yuxin Chen, et al.
Published: (2024-04-01)

Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
by: Shiheng Wu, et al.
Published: (2023-02-01)

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
by: Bárbara M. Schultz, et al.
Published: (2022-08-01)

Sustained spike-specific IgG antibodies following CoronaVac (Sinovac) vaccination in sub-Saharan Africa, but increased breakthrough infections in baseline spike-naive individuals
by: Jackson Sembera, et al.
Published: (2023-11-01)

The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study
by: Yuxiao Wang, et al.
Published: (2023-03-01)

IMUNOFENOTIPAGEM DE LINFÓCITOS B EM RESPONDEDORES E NÃO RESPONDEDORES ANTICÓRPICOS: ESTUDO EM COORTE DE PROFISSIONAIS DA SAÚDE VACINADOS COM CORONAVAC
by: Juliana Ruiz Fernandes, et al.
Published: (2023-10-01)

Body Mass Index, Age, and Gender Affect CoronaVac Vaccine Antibody Response
by: Ayfer ÇOLAK, et al.
Published: (2022-08-01)

Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey
by: Abanoub Riad, et al.
Published: (2021-06-01)

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
by: Chin Shern Lau, et al.
Published: (2022-11-01)

Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers
by: Wisit Prasithsirikul, et al.
Published: (2022-01-01)